Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FLYING BLIND WITH, DELTA???
Most people who get Covid infections after being fully vaccinated have mild to moderate symptoms, and generally have been thought to avoid hospitalizations. But that sense of confidence about vaccine protection was built upon the pre-Delta data when the CDC was monitoring breakthroughs. Still being reported by CDC, from their latest website data, and a constant refrain from public health officials, is that “99.99% of people fully vaccinated against Covid-19 have not had a breakthrough case resulting in hospitalization or death.” That could not be further from the truth. In the July Provincetown Delta outbreaks that the CDC reported on the risk of fully vaccinated requiring hospitalization was 1%, not .01%, and that may not be a reliable estimate for the incidence of such infections occurring throughout the country.
https://amp.theguardian.com/commentisfree/2021/aug/09/america-is-flying-blind-when-it-comes-to-the-delta-variant
Vaccines less than 50% effective getting approval from the FDA???
The global HIV-1 therapeutics market is expected to reach a value of USD 15.8 billion by 2025, growing at a CAGR of 1.4%. According to a new report by Grand View Research, Inc., HIV continues to be one of the most challenging public health issues worldwide.
https://www.grandviewresearch.com/press-release/global-human-immunodeficiency-virus-hiv-1-therapeutics-market
FDA APPROVAL WITH LESS THAN 50% EFFICACY???
https://www.forbes.com/sites/roberthart/2021/07/23/pfizer-shot-just-39-effective-against-delta-infection-but-largely-prevents-severe-illness-israel-study-suggests/amp/
CAN WE HELP THE AFFLICTED???
Some of these people who are now injured after taking a COVID shot used to attack and criticize those who don’t trust the shots, and when encountering information that goes against the corporate media narrative, they used to believe these were all “conspiracy theories.”
But they don’t believe that anymore, now that their lives are ruined.
These are the voices of those who regret their decisions, and their voices are being heavily censored. The “health authorities” don’t want you to listen to them.
So ask yourself, if these shots are so beneficial, why do they need to attack and censor dissenting opinions?
When they claim that all these people who regret taking the shots and are now warning you about them, are “actors” who are lying, what benefit would they receive for faking their injuries? Who would pay them to say these things??
https://medicalkidnap.com/2021/08/18/censored-covid-vaccine-injured-who-regret-their-decisions-to-get-the-shot-and-their-message-to-you/
Vascular dysregulation of the vasa nervorum of the facial nerve is believed to be a central factor in the pathogenesis of Bell's palsy…. Our findings suggest that there must be a vascular regulation in the facial nerve which is controlled by various neuropeptides.
https://pubmed.ncbi.nlm.nih.gov/7684228/
The neuropeptides substance P, calcitonin gene-related peptide (CGRP) and vasoactive intestinal polypeptide (VIP) have been considered as important mediators in migraine and other primary headaches.
https://pubmed.ncbi.nlm.nih.gov/21979827/
Vasoactive intestinal peptide (VIP) is a neuropeptide that exerts various vascular and cardioprotective functions and regulates immune function and inflammatory response at multiple levels. However, its role in inflammatory cardiovascular disorders is largely unknown. Myocarditis and atherosclerosis are two inflammatory and autoimmune cardiovascular diseases that cause important adverse circulatory events…. Systemic VIP treatment reduced the number and size of atherosclerotic plaques in carotid, aorta, and sinus in hypercholesterolemic mice. VIP reduced Th1-driven inflammatory responses and increased regulatory T cells in atherosclerotic arteries and their draining lymph nodes. VIP also regulated cholesterol efflux in macrophages and reduced the formation of foam cells and their presence in atherosclerotic plaques…. These findings encourage further studies aimed to assess whether VIP can be used as a pharmaceutical agent to treat heart inflammation and atherosclerosis.
https://pubmed.ncbi.nlm.nih.gov/29669783/
Note: Zyesami (TM) lacks toxicity and does far more good than a vaccine, does it not? ———
Zyesami (Aviptadil) COVID-19 Therapeutic Description ———
Zyesami (Aviptadil) is a formulation of synthetic human Vasoactive Intestinal Peptide (VIP), which the late Dr. Sami first discovered Said in 1970, for whom ZYESAMI™ is named. Because of its lack of toxicity and low cost of manufacture compared to proprietary biologics, VIP may be uniquely attractive to those focused on global countermeasures against COVID-19, says the company. ———
VIP is known to target the VPAC1 receptor of the alveolar type II cell (ATII) cell and protect that cell against all manner of injuries, including smoke inhalation, exposure to stomach acid, and exposure to infectious agents. In addition, VIP prevents apoptosis, blocks cytokines, lowers TNFa levels, reverses CD4/CD8 ratio, and reduces cough and dyspnea in nonclinical and clinical studies.
https://www.precisionvaccinations.com/vaccines/zyesami-aviptadil-covid-19-therapeutic
Definitions: ————
Apoptosis: the death of cells which occurs as a normal and controlled part of an organism's growth or development. ———
Cytokine: any of a number of substances, such as interferon, interleukin, and growth factors, which are secreted by certain cells of the immune system and have an effect on other cells. ———
TNF: If you have an immune system disease like rheumatoid arthritis (RA), you may have heard your doctor use the term TNF. It's shorthand for tumor necrosis factor, a protein in your body that causes inflammation and helps coordinate the process. ———
CD4/CD8 ratio: A normal CD4/CD8 ratio is greater than 1.0, with CD4 lymphocytes ranging from 500 to 1200/mm 3 and CD8 lymphocytes ranging from 150 to 1000/mm 3. If your ratio is higher than 1, it means your immune system is strong and you may not have HIV. If your ratio is less than 1, you may have: HIV. ———
Macrophages exposed to VIP or PACAP before HIV-1 infection showed resistance to viral replication, comparable to that observed when the cells were treated after infection. Also, multiple treatments with a suboptimal dose of VIP or PACAP after macrophage infection resulted in a decline of virus production similar to the inhibition promoted by a single exposure to the optimal inhibitory concentration. Cellular signaling pathways involving cAMP production and activation of protein kinases A and C were critical components of the VIP and PACAP anti-HIV-1 effects.
https://www.frontiersin.org/articles/10.3389/fimmu.2018.01336/full
Why TFFP and MNKD are Important:
I placed a similar post on this topic yesterday on the NRXP board, but it is equally relevant here. One of the more interesting aspects of following RLFTF and NRXP is their collaboration with each other, and also with other companies. Being relatively small entities, they essentially become a considerable force by partnering up. This also affords investors a window into the development of their products. This isn’t seen with BP where everything is done in house, and behind closed doors. Case in point are the collaborations with TFFP and MNKD. If you go back to the MondoBiotech AG patent #8178489, dated May 15, 2012, you will see that it included freeze drying in the claims. That was 9 years ago. Now fast forward to the present. NRXP is working with TFFP and MNKD, because their freeze drying and encapsulation technologies are patented. If NRXP is successful in applying the TFFP, and MNKD technologies to Zyesami, it will extend, enable and/or broaden the patent protection for this version of aviptadil. From an investing standpoint, you want your money in a product or service that enjoys exclusivity as long as possible. From the recent NRXP conference, Jonathon Javitt:
“We also hope that the formulation work we've done to create ZYESAMI, which is our proprietary stable form of aviptadil, will yield patents that provide additional protection. Lastly, we've announced partnerships with two companies TFF and Mannkind, who have extensive experience in training peptides such as ours into dry powder room temperature stable products that have long-term patent protection.”
It is also in RLFTF’s interest that these product developments are fruitful, through the collaboration agreement with NRXP. So far, it looks like a positive win/win situation to me. ~ Raven, Y@h00 RLFTF finance conversations
“Calculated risk-taking is operationally defined as the ability to deal with incomplete information and act on a risky option, that requires skill, to actualize challenging but realistic goals.” Academics aside, experienced entrepreneurs realize success only comes when taking a leap of faith. Aug 7, 2020
https://www.forbes.com/sites/chriscarosa/2020/08/07/why-successful-entrepreneurs-need-to-be-calculated-risk-takers/
"The proceeds of this investment will be targeted towards accelerating the forward path of our CNS/psychiatry franchise and COVID vaccine franchises, together with supporting the transition of ZYESAMI from clinical to commercial stage as regulatory approval is obtained from national regulators," said Jonathan C. Javitt, MD, MPH, CEO and Chairman of NRx Pharmaceuticals.
https://www.wsj.com/articles/nrx-pharmaceuticals-announces-30-million-private-placement-01629379094
Private placement is a common method of raising business capital by offering equity shares. ... However, stockholders may see long-term gains if the company can effectively invest the extra capital obtained and ultimately increase its revenues and profitability.
https://www.investopedia.com/ask/answers/052815/how-does-private-placement-affect-share-price.asp
By acquiring the rights to AdVita’s therapy formulation, Relief also will accelerate and secure RLF-100’s future development as an inhaled therapy for lung diseases, such as pulmonary sarcoidosis, that are associated with COVID-19. Other lung diseases associated with COVID-19, which also could potentially be treated by RLF-100, include checkpoint inhibitor-induced pneumonitis, and acute respiratory distress syndrome (ARDS).
https://sarcoidosisnews.com/2021/01/28/deal-gives-relief-therapeutics-intellectual-rights-potential-sarcoidosis-therapy-rlf-100/
Conclusions. Asthma and sarcoidosis share many of the same symptoms, as sarcoidosis commonly affects the airways. Therefore, it is problematic to distinguish these two diseases.
https://www.tandfonline.com/doi/full/10.3109/02770903.2012.747204
The etiology of inflammatory diseases of the lung like sarcoidosis and chronic obstructive pulmonary disease (COPD) is multifactorial. The main trigger for developing a COPD is tobacco smoking while exogenous factors causing sarcoidosis are unclear.
https://pubmed.ncbi.nlm.nih.gov/22836641/
The Global Asthma and COPD Drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022. Asthma is a chronic respiratory disease blocking the airways of lung because of inflammation, mucus production, tighten of muscles.
https://www.alliedmarketresearch.com/asthma-COPD-drug-market
Reposting this from -- because it drowns out the noise with facts. Thanks --
From the S-4/A:
"The collaboration will be conducted on an exclusive basis and the parties have agreed not to develop or commercialize any drug product that may be competitive with the Relief Product. "
...
"Pursuant to the Relief Agreement, NeuroRx is responsible for not exceeding the Relief Product trial budget of $8.3 million by more than 30% (approximately $10.7 million) for the original sample size of 144 participants (the ?Initial Budget?)."
"As of May 10, 2021, Relief has reimbursed NeuroRx for approximately $10.6 million of expenses, but has not paid approximately $4 million in invoiced costs associated with conduct of the Relief Product clinical trial, reformulation, and manufacture of ZYESAMI. "
"Each party will continue to own the intellectual property it possessed prior to the collaboration, and any intellectual property that is developed jointly by the parties relating to the Relief Product will be owned jointly by the parties and each party will have the right to use any joint intellectual property in its territory. "
The agreement with $NRXP is quite clear. $RLFTF paid it's share according to the agreement and is entitled to all IP resulting from the collaboration. So any new ZYESAMI formulations are licensed to $RLFTF automatically. ~ WONG, Y@h00 RLFTF finance conversations
Good afternoon from Tel Aviv
This article published in Ukraine last Thursday…
Minister of Health of Ukraine Viktor Lyashko said that his country was among the six states that will be the first to receive a revolutionary drug for the treatment of coronavirus, developed by American companies. The minister made such a statement on August 5 on the air of the Ukraine 24 TV channel.
“We have agreed with manufacturing companies, in particular, these are two companies in the United States, on the supply of innovative drugs to Ukraine for the treatment of COVID-19. These are direct-acting drugs, which are currently in the third stage of clinical trials. We think that this is a breakthrough that, together with vaccination, will allow us to overcome the pandemic, ”Lyashko said. ———
According to him, a quota of 300 thousand courses of treatment has already been reserved for Ukraine. It will be the first direct-acting drug for coronavirus in the country. By the way, in Russia in April 2021 a drug for the coronavirus "Mir-19" was patented. ———
See ALSO: THE MAYOR OF KONOTOP "CUT OFF" THE SERVANT OF THE PEOPLE WITH MUDDY WATER. ———
Over the past day, more than a thousand newly infected with coronavirus have been identified in Ukraine, including 74 children and 32 health workers. In total, during the period of the pandemic, 2 million 256 thousand 397 people fell ill in the country, more than 53 thousand patients died. ———
Read more: https://ukraina.ru/news/20210806/1032011939.html ~ from Ym, Y@h00 RLFTF finance conversations
This is awesome - analysis supporting EUA immediately. "Our findings regarding IL-6 contributions to COVID-related death are consistent with an increasing body of data demonstrating correlation between IL-6 levels and outcome.23 The importance of IL-6 in the pathophysiology of respiratory demise from COVID is further highlighted by the recent Emergency Use Authorization for the IL-6 receptor antagonist tociluzimab (Actemra®, Genentech). Clinical data in support of tociluzimab come from the RECOVERY trial, which showed higher 28-day survival rates (35% vs. 31%) in patients assigned to tociluzimab vs. placebo and the EMPACTA, which showed increased 28-day success rates of 88.0 vs. 80.7%.
Tociluzimab and other IL-6 receptor antagonists block the downstream effects of IL-6 elevation. However, they do not modify the inflammatory processes leading to elevations in IL-6. For example, in one study of IL-6 prior to and following tociluzimab, median IL-6 levels increased, rather than decreased, following treatment, with levels of increase predicting subsequent treatment failure.24 Here, Aviptadil treatment stabilized IL-6 levels leading to increased survival. The relationship between IL-6 and outcome further suggests that it may prove useful in “real time” during treatment to help further optimize Aviptadil dosing across subjects." ~ from Glunker, Y@h00 RLFTF finance conversations
Top of pg. 4 in pre print pdf:
“Aviptadil has been granted compassionate care authorization in the United States and Israel and has been granted Emergency Use Authorization in Georgia, Ukraine, and the Caucasus region, as well as India.”
https://privpapers.ssrn.com/sol3/papers.cfm?abstract_id=3830051
How do you pronounce glyphosate in French???
https://rumble.com/vhsm3h-nobel-laureate-luc-montagnier-warns-covid-vaccine-may-lead-to-neurodegenera.html
A type of disease in which cells of the central nervous system stop working or die. Neurodegenerative disorders usually get worse over time and have no cure. They may be genetic or be caused by a tumor or stroke.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/neurodegenerative-disorder
Glyphosate is an herbicide. It is applied to the leaves of plants to kill both broadleaf plants and grasses. The sodium salt form of glyphosate is used to regulate plant growth and ripen specific crops. ... Glyphosate is one of the most widely used herbicides in the United States.
http://npic.orst.edu/factsheets/glyphogen.html#whatis
Roundup is the brand name of a systemic, broad-spectrum glyphosate-based herbicide originally produced by Monsanto, which Bayer acquired in 2018. Glyphosate is the most widely used herbicide in the United States.
https://en.wikipedia.org/wiki/Roundup_(herbicide)
Manganese (Mn) is an often overlooked but important nutrient, required in small amounts for multiple essential functions in the body. A recent study on cows fed genetically modified Roundup®-Ready feed revealed a severe depletion of serum Mn. Glyphosate, the active ingredient in Roundup®, has also been shown to severely deplete Mn levels in plants. Here, we investigate the impact of Mn on physiology, and its association with gut dysbiosis as well as neuropathologies such as autism, Alzheimer's disease (AD), depression, anxiety syndrome, Parkinson's disease (PD), and prion diseases.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392553/
The main problem is that glyphosate (even according to Monsanto’s research in the 1980’s) accumulates in the body’s tissues. Once in the tissues, the glyphosate substitutes itself for the amino acid glycine when constructing proteins in the body, disrupting the protein manufacturing process that depends on the essential amino acid glycine. This is where the health problems come from. You have heard about the good bacteria in our digestive systems call probiotics. Probiotics build up our gut microbe levels of helpful, healthy bacteria. Glyphosate prevents this from happening causing our health to suffer in many ways.
https://www.healthfirstdc.com/blog/covid-19-and-glyphosate-how-are-they-connected
You may be able to detoxify your body of glyphosate by increasing your dietary intake of glycine. Your body builds new peptides and proteins every day to replace aging ones. Flooding your body with glycine may help to ensure that your body uses the glycine instead of the glyphosate.Mar 14, 2020
https://www.statecollegemagazine.com/articles/is-your-breakfast-toxic/
Scientists are investigating whether chronic inflammation and autoimmune issues are linked to VIP. Find out what role it plays in different tissues in the body and whether certain natural factors can increase it. ——— https://selfhacked.com/blog/vip-a-potent-anti-inflammatory-hormone-and-natural-ways-to-increase-it/
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by extracellular deposits of fibrillary ß-amyloid (Aß) plaques in the brain that initiate an inflammatory process resulting in neurodegeneration. The neuronal loss associated with AD results in gross atrophy of affected regions causing a progressive loss of cognitive ability and memory function, ultimately leading to dementia. Growing evidence suggests that vasoactive intestinal peptide (VIP) could be beneficial for various neurodegenerative diseases, including AD.
https://pubmed.ncbi.nlm.nih.gov/30498985/
The Alzheimer's disease diagnostics and therapeutics market was valued at USD 6,632.82 million in 2020, and it is expected to reach approximately USD 9,073 million in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026.
https://www.mordorintelligence.com/industry-reports/alzheimers-diagnosis-and-drugs-market
In this respect, vasoactive intestinal peptide has beneficial effects that provide an advantage for the treatment of Parkinson's disease. Vasoactive intestinal peptide is a major neuropeptide-neurotransmitter having antioxidant, anti-inflammatory, neurotropic, neuromodulator, and anti-apoptotic properties.
https://pubmed.ncbi.nlm.nih.gov/30636594/
113 Pages Report] The Parkinson's disease treatment market was valued at USD 3.99 billion in 2016 and expected to grow at a CAGR of 6.1% from 2017 to 2022 to reach USD 5.69 billion in 2022. The carbidopa/levodopa drug class is projected to register highest CAGR during forecast period.
https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html
Dr Fauci, we don’t have a pill but, we have an infusion of Zyesami (TM) that takes care of COVID-19 and then some!!
About APPLIED PHARMA RESEARCH a Relief Therapeutics Holding AG company ——— Despite the success of laser refractive surgery to correct low order aberrations,
the incidence of postoperative symptoms remains to be relatively high.
EYE LASER SURGERY
In particular, estimates indicate that 53% of patients experienced at least one side effect within the first four weeks after surgery, as well as 22% experienced them six months after surgery, especially related to the inflammation and corneal healing.
These visual outcomes can reduce the quality of life of patients and are a key factor impacting the poor level of satisfaction of surgery.
Current treatments are antibiotic and corticosteroids, which however can have side effects, the former causing resistance while the latter causing delay in healing and worsening infections.
https://www.apr.ch/apr-pharma-products/therapeutic-pharma/eye-laser-surgery/
The regulatory role of vasoactive intestinal peptide in lacrimal gland ductal fluid secretion: A new piece of the puzzle in tear production ——— Vasoactive intestinal peptide (VIP) is an important regulator of lacrimal gland (LG) function although the effect of VIP on ductal fluid secretion is unknown. Therefore, the aim of the present study was to investigate the role of VIP in the regulation of fluid secretion of isolated LG ducts and to analyze the underlying intracellular mechanisms.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722779/
THE AMAZING NEUROPEPTIDE ——— VIP plays an important role in visual development. Nasal administration of VIP can improve the function of neurons in the LGBd of kittens and has a certain therapeutic effect on amblyopia.
https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-019-1203-1
Global Amblyopia Market was valued at USD 4327.0 Million in 2016, and is forecasted to grow at CAGR of 3.28% over the forecast period 2020-2026. The key factors driving the market growth include growing prevalence of ophthalmological disorders, increasing technological advancement and high healthcare expenditure.
https://dataintelo.com/report/amblyopia-market-report/
MORE ON VIP INFUSIONS ——— Dialysis requiring renal failure is a silent epidemic. Despite an annual mortality of 24% the dialysis population has increased by 1–4% per annum. Regardless of the initial injury, tubulointerstitial fibrosis is a feature of the renal pathology and it inversely correlates with declining renal function. Current agents display little efficacy against tubulointerstitial fibrosis. Clearly, therapies effective against tubulointerstitial fibrosis and able to preserve kidney function are needed. Vasoactive intestinal peptide (VIP) has been shown to reverse pre-existing cardiac fibrosis.
https://www.sciencedirect.com/science/article/pii/S0014299920300716
The global market for chronic kidney disease should grow from $79.0 billion in 2018 to reach $95.0 billion by 2023 at a compound annual growth rate (CAGR) of 3.8% for the period of 2018-2023.
https://www.bccresearch.com/market-research/healthcare/chronic-kidney-disease-market-research-report.html
IS IT THE DELTA VARIANT??? …hide itself once inside…??? ———
What has emerged from 19 months of work, backed by decades of coronavirus research, is a blow-by-blow account of how SARS-CoV-2 invades human cells (see ‘Life cycle of the pandemic coronavirus’). Scientists have discovered key adaptations that help the virus to grab on to human cells with surprising strength and then hide itself once inside. Later, as it leaves cells, SARS-CoV-2 executes a crucial processing step to prepare its particles for infecting even more human cells. These are some of the tools that have enabled the virus to spread so quickly and claim millions of lives. “That’s why it’s so difficult to control,” says Wendy Barclay, a virologist at Imperial College London.
https://www.nature.com/articles/d41586-021-02039-y
Zyesami (Tm) is A VIP analog, “Delta can run but, can it hide…???” ———
Vasoactive intestinal peptide (VIP) has recently been shown to bind to human lymphocytes and modulate immune functions. The ability of VIP in restoring natural killer (NK) cell activity depressed by hepatitis B surface antigen (HBsAg) has been investigated in the present research.
https://pubmed.ncbi.nlm.nih.gov/1418317/
Zyesami (Aviptadil) COVID-19 Therapeutic Description
Zyesami (Aviptadil) is a formulation of synthetic human Vasoactive Intestinal Peptide (VIP), which the late Dr. Sami first discovered Said in 1970, for whom ZYESAMI™ is named. Because of its lack of toxicity and low cost of manufacture compared to proprietary biologics, VIP may be uniquely attractive to those focused on global countermeasures against COVID-19, says the company.
VIP is known to target the VPAC1 receptor of the alveolar type II cell (ATII) cell and protect that cell against all manner of injuries, including smoke inhalation, exposure to stomach acid, and exposure to infectious agents. In addition, VIP prevents apoptosis, blocks cytokines, lowers TNFa levels, reverses CD4/CD8 ratio, and reduces cough and dyspnea in nonclinical and clinical studies.
https://www.precisionvaccinations.com/vaccines/zyesami-aviptadil-covid-19-therapeutic
Effective Covid-19 treatments that help protect lungs in hospitalizations and against long-Covid are really in demand. Long Covid-19 can reduce patients to effectively be disabled and even decrease their intelligence with “brain fog” among other symptoms. It’s not clear how grave an effect long covid will have on the global economy in terms of productivity at scale.
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate, RLF-100 TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. Zyesami, its commercial name, has turned out to be one of the most effective treatments for serious Covid-19 cases. You can see their website here.
As more countries get EUA for Zyesami it’s only a matter of time until major European countries and the U.S. and other countries in grave danger approve it — like Indonesia, India, Russia, Brazil and others.
https://lastfuturist.com/relief-therapeutics-eua-for-zyesami-expanding-to-more-countries/
WhosJohnGalt, I hope your thirteenth attempt turns out to be your most fortunate. And for all RLFTFers as well! ——— The Significance of Vasoactive Intestinal Peptide in Immunomodulation
https://pharmrev.aspetjournals.org/content/56/2/249
This week, we are responding to an FDA information request for various, supplemental statistical analyses regarding the Phase 2b/3 data. In our experience, such requests are a routine part of the regulatory process and indicative of active engagement by the regulator.
https://www.nrxpharma.com/
It must be understood that additional information and not additional data is required here! When can I request additional information? Only when I have read through the entire 59k pages and am sure that the information I would like to have is not included. Do I request additional information if the existing data is not sufficient for an EUA anyway? No! We are close to the decision and the signs are more than good! ~ Rinaldo from Y@h00 RLFTF finance conversations
Ms Pegs1, how do you start a Zyesami (TM) wave??? With the Georgian nation, of course!! Whoa!!
IMO, the reasons for the maximum amount of time being used by the FDA in their decision making process, are twofold. ———
First, reviewing and verifying Trial Data takes an enormous amount of time…it is TRULY a Herculean effort to accomplish this task for a Fast Track Therapeutic. We’re approaching 60-days at the end of this week, and being among the group of Fast Track Therapeutics, we should technically have our answer by Friday. “Technically.” ———
Second, and likely equally important, the FDA and the current Presidential Administration would like to have as many people as possible vaccinated before rolling out a truly efficacious (i.e., unlike Remdesivir) COVID Therapeutic. ———
Posit: If you were an anti-vaxer, how likely would it be that you would EVER consider a SARS Co-V-2 vaccine knowing there is a Therapeutic (i.e., Zyesami/Aviptadil) that is highly likely to cure you of COVID should you become ill? ———
Answer: Highly unlikely. ———
And while Zyesami/Aviptadil WILL cure many…not necessarily all, especially among those with complicating comorbidities, but many will be cured…then that leaves a WHOLE Lot of unvaccinated people who are free to continue distributing/infecting the general public at large everywhere they go until they themselves develop COVID symptoms, and can be treated by our little Gem here. ———
I’m curious as to what you all may think/feel about my squirrelly ?? notions. I’m on vacation with my family, so I won’t be able to reply until later this evening. But my “Thanks” to all in advance for your thoughts on these matters. ———
And, for the Longs here…we’ve all done our DD. We know what we own. Don’t be frazzled by all of the “tools” here in large numbers trying to separate us from our invested dollars/Francs on a daily basis. I truly do believe it’s simply a waiting game at this point. ———
—Cheers—
~~~ Brian A, from Y@h00 RLFTF finance conversations
ACER is then the big rock upon which RLFTF will be built, great!!
APR-AOS2020 as mention trial completion est July 31st (possible PR catalyst) Human clinical studies as well as in vitro and in vivo safety tests have demonstrated that APR-AOS2020 has a very good safety profile on various human tissues with a cytotoxicity index of up to 20 times lower than other marketed antimicrobial solutions. ————
"Based on these encouraging data, we have designed a pivotal, monocentric, randomized, controlled clinical study to assess whether the spray solution, used to irrigate, hydrate and cleanse nasal mucosa for three or five times a day at regular intervals, is safe and effective in patients positive to SARS-CoV-2 with mild symptoms, in addition to the standard therapies, to reduce the nasal viral load – says Professor Giancarlo Icardi, Director of the Hygiene Unit of the IRCCS Policlinico San Martino Hospital in Genoa, lead investigator – Reducing the viral load in the nose, thanks to either the mechanical cleansing mechanism combined with the antimicrobial efficacy of the HCLO, could prevent the insurgence of more severe symptoms and improve the course of the disease in its initial phase, reducing also the risk of spreading the infections to other individuals. If SARS-CoV-2 viral load in the upper respiratory airways is lower, it is likely that the probability of the virus to enter the lower airways damaging lungs is reduced. The nasal spray, when used in the initial phase of infection or after exposure to risk of infection, could reduce the probability of becoming infected, the worsening of symptoms and the spread of the infection to other individuals". —————
"We believe that this innovative device, which is designed to be affordable and easy to use, could represent an additional near-term protective option that could be particularly helpful in high-risk environments such as public transportation, shops, schools and other crowded, closed spaces", says Paolo Galfetti, CEO of APR. "The initiation of this controlled, randomized clinical trial gets us closer to the objective of making this product available before year end specifically for use against COVID-19." ~ smartest man alive, from Y@h00 RLFTF finance conversations
Update of the ValuationLab report on Relief (July 26), NPV 0.76 CHF
https://www.valuationlab.com/research/.
~ Bert-Jan, from Y@h00 RLFTF finance conversations
The next catalyst???
From Dr. Joey's video:
Did you know that the Sentinox (nasal spray) trial from APR has a completion date set at July 31st?
https://clinicaltrials.gov/ct2/show/NCT04909996?term=sentinox&draw=2&rank=1
~From Bert-Jan, Y@h00 RLFTF finance conversations
Is ACER the vehicle for RLFTF uplist???
https://wallstreetharold.com/2021/03/acer-stock-acer-therapeutics-could-merge-with-relief-therapeutics/
Hear! Hear! RLFTF
It takes three doses of IV Zyesami for a treatment regimen per patient, let's assume $8,000 per dose as the cost has come down. The USA has 50 states and each state's hospitals would (in my opinion) want an average of 30,000 doses as a stockpile or 1,5 million doses, enough to treat 10,000 people in each state or half a million in the United States. $12 billion in sales. The DARPA/BARDA has initiated a stockpiling order for 430,000 doses. $3.4 billion in sales. Assuming the EU wants the same as the USA, $12 billion in sales. Rest of the world, let's assume another 1.5 million doses or $12 billion. the point of this is to show that without a lot of salesmanship or promotion, our two companies could initiate world wide sales of around $40 billion for a combination of stockpiling and hospital inventory. Not taking into account the different percentages in our favor, dividing by half and half again for a 50% profitability.... we see earnings of $10 billion this year even with us in July/August if, and it's a big if we can produce 5 million doses before year end. What would that equate to in share price and market cap for these companies? North of $40 up to $80 billion. Remembering that these professionals will uplist this company in a heartbeat once it is in their/our advantage and we haven't even begun discussing the inhaled version for covid nor all of the other indications we are aware of and for this company the add on "other" drugs in our pipeline. I don't think it is unreasonable to assume a market cap in the $50 to $80 billion range assuming what we can see on the horizon and with the pandemic still raging across the world. Actually, since we have the greater earnings potential with the contractual agreement we could see $100 billion on a 10X forward earnings. All of these assumptions are just that, the price, the sales, where the sales will originate, but in thinking about where one might want to sell and why... it is good to consider these kind of ideas so one doesn't sell out too soon. Having been here a year and paid dearly in patience and reduced lifestyle, I personally want to make sure I maximize this investment for all it's worth. I'm inclined to think $10.00 to $20.00 are more worthy exit points than $3.00 to $5.00 as many, including myself, have considered in the past. I've considered 4 billion as the # of shares outstanding.
Again, just food for thought, contemplating something to compare against what is about to occur once the EUA is granted. A guide for myself. Possibly it will tickle your brain to make a more informed decision. That is my hope.
~ Zaran, Y@h00 RLFTF finance conversations
Waiting for $20 ~ Francesco, Y@h00 RLFTF finance conversations
B cells are at the centre of the adaptive humoral immune system and are responsible for mediating the production of antigen-specific immunoglobulin (Ig) directed against invasive pathogens (typically known as antibodies).
https://www.immunology.org/public-information/bitesized-immunology/cells/b-cells
We conclude that systematic approaches to identify the key physicochemical degradation mechanism(s) of formulated mRNA vaccine candidates are currently lacking.
https://www.sciencedirect.com/science/article/pii/S0022354920307851
When the Pfizer vaccine is received at hospitals, it has to be reconstituted or mixed to allow injection, and then stored at temperatures between 2 to 8 ºC. At this temperature, their expiration is five days, while at room temperature, their expiration is only two hours.
https://www.news-medical.net/news/20210617/How-stable-are-mRNA-vaccines-under-continuous-movement.aspx
Agreed El Cappy!! RLFTF
WELL PUT MS PEGS1!! ——— Immunoglobulins, also known as antibodies, are glycoprotein molecules produced by plasma cells (white blood cells). They act as a critical part of the immune response by specifically recognizing and binding to particular antigens, such as bacteria or viruses, and aiding in their destruction.
https://www.thermofisher.com/us/en/home/life-science/antibodies/antibodies-learning-center/antibodies-resource-library/antibody-methods/introduction-immunoglobulins.html
Vasoactive intestinal peptide stimulates immunoglobulin production and growth of human B cells
https://pubmed.ncbi.nlm.nih.gov/1311995/
Do vaccines block cytokine storms??? ——— Data from Randomized Phase 2b/3 Trial Shows Patients Treated with ZYESAMI™ are Significantly Less Likely to Experience IL-6 Cytokine Rise, and Have Improved Survival and Recovery from Respiratory Failure, Compared to Patients Receiving Placebo
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-presents-evidence-zyesami-aviptadil-helps-prevent-cytokine-storm-in-patients-with-covid-19-301336297.html
DO VACCINES HELP RECOVERY FROM PNEUMONIA??? ———
Pneumonitis (noo-moe-NIE-tis) is a general term that refers to inflammation of lung tissue. Technically, pneumonia is a type of pneumonitis because the infection causes inflammation. Pneumonitis, however, is usually used by doctors to refer to noninfectious causes of lung inflammation.~Mayo Clinic
https://www.nejm.org/doi/full/10.1056/NEJMc2000343
WILL ZYESAMI(TM) END THE COVID-19 PANDEMIC???
https://www.wsj.com/articles/nrx-pharmaceuticals-announces-first-successful-commercial-formulation-for-zyesami-tm-aviptadil-enabling-volume-manufacture-shipping-and-stockpiling-of-covid-19-medication-subject-to-regulatory-approval-01626950910
VACCINES MARKET SIZE
The global vaccines market size is expected to reach USD 73.78 billion in 2028, registering a CAGR of 7.3% over the forecast period, according to the latest report by Reports and Data.
https://www.globenewswire.com/en/news-release/2021/06/02/2240725/0/en/Vaccines-Market-Size-to-Reach-USD-73-78-Billion-in-2028-Increasing-government-funding-for-vaccine-production-and-growing-emphasis-on-immunization-are-major-factors-expected-to-driv.html
Yes, I stand corrected, he did say a 15 to 1 reverse split, a stock buy back program and other ways too early to mention.
The fastest way to up listing and no mention of a reverse split!!
About Zyesami (TM)
——— Tony ———
Have a friend on a ventilator with covid. Otherwise healthy 59 year old male. I’m sure this has been asked. Where or can he access Zyesami? ——— Reply———
while it is easier to get it when the patient is on a vent or ECMO, be prepared to get total resistance from the doctor. dont NOT try to go through your doctor, you have to get neurorx on board first directly, your doctor will say no a hundred times. once neurorx is committed to getting it to you, the doctor will still resist. the hospital has to have a board meeting for every patient that gets an eIND drug, thats the protocol, and the doctor has to fill out reams of paperwork....thats why they have no desire to go down this road...dont take no for an answer, especially if neurorx has committed
good luck, its doable
——— Reply———
Contact Robert E Besthof at NeuroRx. He is the person in charge of this. I have been fortunate to talk with him and have some very minor contact with Dr. Javitt who referred me to Mr. Besthof. The company is working with people through the Right to Try federal law. it is the fastest way to get the drug to the patient.
——— Reply ———
After reading this question many times, I believe the best option is to contact Neurorx directly. Ive read that they are responsive and that dr JJ sometimes helps if the hospitals/doctors are giving you a hard time
https://www.nrxpharma.com/contact-us/
good luck!
——————
Tony from Y@h00 finance conversations
The global influenza vaccine market size was valued at $3.96 billion in 2018, and is projected to reach $6.20 billion by 2026, registering a CAGR of 5.9% from 2019 to 2026.
https://www.alliedmarketresearch.com/influenza-vaccines-market
The global Influenza Therapeutics market size is projected to reach US$ 9521.1 million by 2027, from US$ 6644.2 million in 2020, at a CAGR of 4.8% during 2021-2027. Influenza, commonly known as the flu, is an infectious disease caused by an influenza virus.
https://www.marketwatch.com/press-release/influenza-therapeutics-market-size-growing-at-48-cagr-to-hit-usd-95211-million-by-2027-2021-07-12
THE SIGNIFICANCE OF VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) IN IMMUNOMODULATION ——— Evidence for VIP influences on immune function comes from studies demonstrating VIP-ir nerves in lymphoid organs in intimate anatomical association with elements of the immune system, the presence of high-affinity receptors for VIP, and functional studies where VIP influences a variety of immune responses. Anatomical studies that examine the relationship between VIP-containing nerves and subpopulations of immune effector cells provide evidence for potential target cells. Additionally, the presence of VIP in cells of the immune system that also possess VIP receptors implies an autocrine function for VIP. The functional significance of VIP effects on the immune system lies in its ability to help coordinate a complex array of cellular and subcellular events, including events that occur in lymphoid compartments, and in musculature and intramural blood circulation.
https://pubmed.ncbi.nlm.nih.gov/8790778/